Atorvastatin

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 5, 2001, Pages 819-830

  Wierzbicki, A S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Atorvastatin; HMG CoA reductase inhibitor; LDL cholesterol; Myocardial infarction; Statin

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTIMITOTIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CERIVASTATIN; CHOLESTEROL; CYTOKINE; FATTY ACID DERIVATIVE; FLUINDOSTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NITRIC OXIDE; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; CONTROLLED STUDY; CORONARY ARTERY DILATATION; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; SIDE EFFECT; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; CHOLESTEROL, LDL; CLINICAL TRIALS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DRUG INTERACTIONS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PYRROLES;

EID: 0034872405     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.5.819     Document Type: Article

References (90)

1. The impending global epidemic of cardiovascular disease
2. Aortic stenosis. An atherosclerotic disease?
3. The pathogenesis of atherosclerosis: A perspective for the 1990s
4. Atherosclerosis - An inflammatory disease
5. Atherosclerosis: Basic mechanisms. Oxidation, inflammation and genetics
6. Assessment and treatment of endothelial dysfunction in humans
7. Compensatory enlargement of human atherosclerotic coronary arteries
8. Noninvasive detection of atherosclerosis
9. Mechanisms of calcification in atherosclerosis
10. Electron beam tomography as an end point for clinical trials of anti-atherosclerotic therapy
11. Coronary plaque disruption
12. Cholesterol reduction in cardiovascular disease
13. Familial hypercholesterolaemia
14. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: Five-year post-trial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias
15. Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease
16. Statin trials and goals of cholesterol-lowering therapy
17. Editorial. Is a statin a statin?
18. ML-236A, ML-236B, ML-236C, new inhibitors of cholesterologenesis produced by Penicillium citrinum
19. Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor
20. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
21. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs
22. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
23. Comparison of statins in hypertriglyceridemia
24. High-density lipoprotein cholesterol and triglyceride response with Simvastatin vs. Atorvastatin in familial hypercholesterolemia
25. Action of atorvastatin in combined hyperlipidemia: Preferential reduction of cholesteryl ester transfer from HDL to VLDL-1 particles
26. Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male but not in female patients with familial hypercholesterolemia
27. Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias
28. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia
29. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-1 levels
30. HDL Cholesterol and the treatment of coronary heart disease
31. Anti-atherothrombotic properties of statins. Implications for cardiovascular event reduction
32. Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins
33. Effects of statins on C-reactive protein in patients with coronary artery disease
34. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
35. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia
36. Vastatins inhibit tissue factor expression in cultured human macrophages
37. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia
38. Atorvastatin but not L-arginine improves endothelial function in Type I diabetes mellitus: A double-blind study
39. Atorvastatin: An effective lipid-modifying agent in familial hypercholesterolemia
40. Effect of atorvastatin on plasma fibrinogen
41. Statins and fibrinogen
42. More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia
43. Statins and fibrinogen
44. The effect of atorvastatin on serum lipids, lipoprotein (a) and plasma fibrinogen levels in primary dyslipidaemia- a pilot study involving serial sampling
45. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin
46. Cholestatic liver dysfunction
47. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin
48. An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor
49. Statins and peripheral neuropathy
50. Effects of lovastatin on the immune system
51. Link between heart disease, cholesterol and Alzheimer's disease: A review
52. Stimulation of bone formation in vitro in rodents by statins
53. Do statins prevent both cardiovascular disease and fracture?
54. New insights into the pharmacodynamic and pharmacokinetic properties of statins
55. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: A comparison of atorvastatin and simvastatin
56. New statins and new doses of older statins
57. Pharmacodynamic effects and pharmacokinetic of atorvastatin after administration to normocholesterolemic subjects in the morning and evening
58. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin
59. Does differing metabolism by cytochrome P450 have clinical importance
60. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities
61. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: An in vitro investigation with human liver preparations
62. Atorvastatin does not alter the anticoagulant activity of warfarin
63. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study)
64. AVERTing angioplasties: Are statins better than procedures?
65. Atorvastatin versus revascularization treatment (AVERT): Fact or fancy?
66. The AVERT trial
67. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial
68. Unstable angina - A definitive role for statins in secondary prevention
69. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes
70. Statin trials in progress: Unanswered questions
71. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia
72. Pleiotropic effects of statins in atherosclerosis and diabetes
73. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients
74. Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Project
75. Role of lipid lowering in transplantation
76. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation
77. Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis
78. Hyperlipidaemia associated with HIV protease inhibitor use: Pathophysiology, prevalence, risk factors and treatment
79. Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety
80. Cost of treating to a modified European Atherosclerosis Society LDL-C target
81. An assessment of the efficacy of atorvastatin in treating patients with dyslipidaemia to target LDL-cholesterol goals: The Atorvastatin Matrix study
82. Treating patients with documented atherosclerosis to National Cholesterol Education Program - Recommended low-density-lipoprotein goals with atorvastatin, fluvastatin, lovastatin and simvastatin
83. Cost-effectiveness of statins
84. Safety of low-density lipoprotein reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial)
85. Are drugs within a class interchangeable?
86. Are drugs interchangeable?
87. Natural statins and stroke
88. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel II)
89. Prevention of coronary heart disease in clinical practice. European recommendations revised and reinforced
90. Recommendations on prevention of coronary heart disease in clinical practice